TELA Bio Reports Q4 and FY25 Financial Results with 18% YoY Revenue Growth and Expanded Sales Force

TELA Bio reported Q4 and full-year 2025 financial results, with revenue of $20.9 million and $80.3 million, an 18% and 16% increase, respectively, from the corresponding periods of 2024. The company expanded its sales force to 88 quota-carrying representatives and announced the promotion of Howard Langstein, MD, FACS to Chief Medical Officer. TELA Bio also closed a credit facility for up to $70 million from Perceptive Advisors.